This program is working to expand the number of therapies designed to fix the defective CFTR protein in people who have the F508del mutation. 

Status

Laboratory studies to develop and test these compounds are underway. 

Sponsor

This program is sponsored by Reata Pharmaceuticals and partially funded by Cystic Fibrosis Foundation Therapeutics (CFFT). 

Contact us about Reata >